Alan is a veteran in healthcare related investments. He is Founder/Managing Partner at GT Healthcare Partners, an innovative private equity operator focusing on cross border healthcare investments.. Alan was senior adviser to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE:SCR, privatized in. Dec 2013, when Alan was Chairman of the Special Committee on the Board of Directors). He was also a member of the Board, Audit Committee and Compensation Committee of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in Sep 2016) from 2013 to 2016. Separately, Alan is a member of the Board, Audit Committee and Chairman of Nomination Committee of Cellular BioMedicine Group Inc. (Nasdaq: CBMG), a leader in immune-oncology in China. In addition, he has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014.. Before that, Alan was Head of Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region between 2011 and 2012. Prior to that, he was Executive Director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010, and Investment Director at Morningside Group, managing healthcare investments in Asia from 2000 to 2005. From 1995 to 1999, Mr. Au worked at KPMG and KPMG Corporate Finance Ltd., taking care of regional M&A transactions and financial advisory services.. Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Alan received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong, and a Master’s degree in Management from Columbia Business School in New York.
